Mark J. Rosenblum - 20 Feb 2024 Form 4 Insider Report for Salarius Pharmaceuticals, Inc. (SLRX)

Role
Exec VP Finance, CFO
Signature
/s/ Mark J. Rosenblum
Issuer symbol
SLRX
Transactions as of
20 Feb 2024
Transactions value $
$0
Form type
4
Filing time
22 Feb 2024, 16:37:10
Previous filing
15 Feb 2023
Next filing
20 Nov 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SLRX Stock Option (right to buy) Award $0 +22.5K $0.00 22.5K 20 Feb 2024 Common Stock 22.5K $0.57 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the options are vested on February 20, 2025, and 1/36 of the remaining options vest on each monthly anniversary thereafter for 36 months.